Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma

BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation. Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Ling, Xie, Liping, Zuo, Chuan, Ma, Zhigui, Zhang, Yanle, Zhu, Yiping, Gao, Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506760/
https://www.ncbi.nlm.nih.gov/pubmed/26189041
http://dx.doi.org/10.1186/s12885-015-1535-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506760/
https://www.ncbi.nlm.nih.gov/pubmed/26189041
http://dx.doi.org/10.1186/s12885-015-1535-z

Ejemplares similares